伊宁怀孕2天不要怎么办(伊宁如果怀孕了什么时候能测出来) (今日更新中)

The U.S. recorded more than 120,000 new cases of COVID-19 on Thursday as cases continue to skyrocket across the country.According to Johns Hopkins University, there were 121,888 new cases of COVID-19 recorded across the country on Thursday. That shatters the previous record of 102,000 cases that were reported on Wednesday.Johns Hopkins reports that more than 1,200 people died of the virus in the U.S. on Thursday, the highest death total since Sept. 15. The highest daily death total throughout the pandemic occurred on April 15, when 2,600 people died.According to Johns Hopkins, COVID-19 is currently spreading faster in the U.S. than it is anywhere else in the world. The U.S. has recorded an average of about 80,000 new cases of COVID-19 in the last seven days; the country with the second-highest rate of new cases is India, with an average of about 45,000 new cases of the virus each day.Health officials warn that the U.S. is entering what could be the most dangerous and deadly period of the pandemic, as colder weather forces social gatherings indoors, where the virus is more easily spread.Since the start of the pandemic, there have been 9,606,369 cases reported in the US, 234,911 being fatal. Both totals mark the most of any country. 1258

The University Hospitals Fertility Clinic in Cleveland is facing dozens of legal actions after the failure in early March of a cryopreservation tank containing approximately 4,000 eggs and embryos belonging to at least 950 families."We currently represent well over 100 clients whose cases we will pursue as individual claims. That number is growing by the day," Cleveland attorney Tom Merriman said Monday.Also Monday, attorney Gloria Allred threw her hat into the ring, announcing litigation on behalf of three Pittsburgh women who are all cancer survivors. 567

The Tulsa Athletic, a semi-pro soccer team in Oklahoma, announced on Wednesday that they will no longer play 'The Star-Spangled Banner' before home matches.Team officials said they want to ensure an inclusive environment for athletes, supporters, and the community. 273

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The U.S. government’s auto safety agency is investigating complaints that headlights can suddenly fail in some older Kia SUVs. The National Highway Traffic Safety Administration says the probe covers about 392,000 Kia Sorento SUVs from the 2011 through 2013 model years. The agency says it has 74 reports of failures that may be related to connectors overheating. There were no reports of crashes or injuries. Some complaints allege that both headlights went out in the middle of turns or while traveling on the highway. In a statement, Kia says its cooperating, and its own investigation shows that both headlights have not gone dark at the same time. U.S. investigators will determine how often the problem happens and look into the safety consequences. 763

来源：资阳报